The next course an "Update on Pharmacoeconomics in the Irish Healthcare Setting" will take place on 10th and 11th March 2016. Now taking bookings. Please click here for draft programme 2016.
The NCPE recommends reimbursement of pembrolizumb for the first line treatment of unresectable or advanced metastic melanoma.
The NCPE does not recommend the reimbursement of pembrolizumab for this indication at the submitted price.